New hope for aggressive blood cancer complication
NCT ID NCT04679012
Summary
This study is testing whether adding a targeted drug called polatuzumab vedotin to standard chemotherapy works better for people with Richter's transformation, a serious complication where chronic lymphocytic leukemia turns into a more aggressive lymphoma. About 20 adults with this condition will receive the drug combination in 21-day cycles for up to six cycles. Researchers will monitor how well the treatment works and how safe it is, following participants for several years to track survival and long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact
-
Mount Sinai- Icahn School of Medicine
RECRUITINGNew York, New York, 10029, United States
Contact
Contact
-
Ohio state University
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.